Summary

The addition of a vascular endothelial growth factor antibody and an epidermal growth factor receptor inhibitor to chemotherapy had no benefit in advanced colorectal cancer. In fact, the combination had a significantly negative effect on progression-free survival. This article discusses the results of CAIRO2 [NCT00208546], a trial that was designed to investigate the effect of adding cetuximab to chemotherapy plus bevacizumab.